{"id":"https://openalex.org/W199842010","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","title":"Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC).","display_name":"Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W199842010","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","mag":"199842010"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.4665","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022820783","display_name":"Farshid Dayyani","orcid":"https://orcid.org/0000-0002-4970-5189","observed_orcids":["https://orcid.org/0000-0002-4970-5189"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Dayyani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111690153","display_name":"Gary E. Gallick","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. E. Gallick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049881937","display_name":"Jerry T. Thompson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. T. Thompson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107861053","display_name":"Geralyn Carol Trudel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. C. Trudel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111743098","display_name":"Christopher J. Logothetis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Logothetis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5048915309","display_name":"John C. Araujo","orcid":"https://orcid.org/0000-0001-9361-3364","observed_orcids":["https://orcid.org/0000-0001-9361-3364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. C. Araujo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"4665","last_page":"4665"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9599999785423279},{"id":"https://openalex.org/keywords/interleukin-8","display_name":"interleukin-8","score":0.9710000157356262},{"id":"https://openalex.org/keywords/mcp-1","display_name":"MCP-1","score":0.9940000176429749},{"id":"https://openalex.org/keywords/peak-drug-concentration","display_name":"peak drug concentration","score":0.5339999794960022},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.746999979019165},{"id":"https://openalex.org/keywords/src-family-kinase-inhibitor","display_name":"Src family kinase inhibitor","score":0.7459999918937683},{"id":"https://openalex.org/keywords/bone-turnover-markers","display_name":"bone turnover markers","score":0.5809999704360962},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6069999933242798},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.39899998903274536},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.7179999947547913},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.48100000619888306},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.31299999356269836},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8417624235153198},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.7304829359054565},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7284839153289795},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.5914469361305237},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5072993636131287},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45416292548179626},{"id":"https://openalex.org/C2781184567","wikidata":"https://www.wikidata.org/wiki/Q107244","display_name":"Monocyte","level":2,"score":0.4125525951385498},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.37511008977890015},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34198498725891113},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3243737816810608},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.4665","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.4665","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2258563421","https://openalex.org/W2074429860","https://openalex.org/W2010416238","https://openalex.org/W2244252446","https://openalex.org/W2589867709","https://openalex.org/W2031569848","https://openalex.org/W2118263555","https://openalex.org/W2537692172","https://openalex.org/W1987008543","https://openalex.org/W2591239607"],"abstract_inverted_index":{"4665":[0],"Background:":[1],"IL-8":[2,64,79,155,217,299,316],"has":[3],"been":[4],"reported":[5],"to":[6,177,345],"promote":[7],"CRPC":[8,54,121,341],"growth":[9,34],"[Am":[10],"J":[11],"Path1999;1503].":[12],"Further,":[13],"MCP-1":[14,66,81,157,220],"mediates":[15],"tumor-":[16],"induced":[17,38],"osteoclastogenesis":[18],"and":[19,35,80,95,122,135,150,156,169,191,199,219,241,300,336,342],"bone":[20,36,247,261],"resorption":[21],"[Cancer":[22],"Res":[23],"2007;3646].":[24],"Dasatinib":[25],"(DAS),":[26],"a":[27,89,214,226,256,304,347],"potent":[28],"SRC-family":[29],"kinase":[30],"inhibitor,":[31],"affects":[32],"tumor":[33],"turnover":[37,262],"by":[39,43],"CRPC,":[40],"the":[41,49,71,84,143,260,286,294,297,329],"latter,":[42],"potentially":[44],"blocking":[45],"osteoclast":[46],"activation":[47],"Thus,":[48],"effects":[50],"of":[51,62,88,93,100,133,164,205,259,269,275,285,296,306,315,334],"DAS":[52,76,94,134,147,194,206,276,289,309,335,351],"in":[53,56,83,216,234,243,267,281,288,320,328,338],"might":[55,317,343],"part":[57],"be":[58,318,326,346],"mediated":[59],"through":[60],"reduction":[61],"either":[63],"and/or":[65],"levels.":[67],"Here,":[68],"we":[69],"analyzed":[70,105],"correlation":[72,173],"between":[73],"serum":[74,313],"peak":[75,193],"levels":[77,82,124,158,195,207,221,290],"with":[78,119,213,237,246,293,340],"phase":[85,90,331],"II":[86],"portion":[87],"I/II":[91],"study":[92],"docetaxel":[96],"(D)":[97],"for":[98,106,142,185,188,308,350],"treatment":[99],"metastatic":[101],"CRPC.":[102,282],"Data":[103],"was":[104,146,175,183,232,265],"patients":[107],"enrolled":[108,253],"at":[109,167,254],"M.":[110],"D.":[111,311],"Anderson":[112],"Cancer":[113],"Center":[114],"(MDACC).":[115],"Methods:":[116],"Male":[117],"pts":[118,145,187,224,236,245,252,339],"progressive":[120],"testosterone":[123],"\u226450":[125],"ng/dL":[126],"requiring":[127],"chemotherapy":[128],"were":[129,137,159,196,210],"enrolled.":[130],"Escalating":[131],"doses":[132,140],"D":[136,151,278,337],"evaluated.":[138],"The":[139,172,273,283,312],"selected":[141],"included":[144],"100mg":[148],"QD":[149],"75mg/m2":[152],"Q21D.":[153],"DAS,":[154],"measured":[160],"on":[161],"day":[162],"14":[163],"cycle":[165],"1,":[166],"0":[168],"2hrs,":[170],"post-administration.":[171],"coefficient":[174],"calculated":[176],"establish":[178],"linear":[179],"relationship.":[180],"Results:":[181],"Serum":[182],"available":[184],"18/33":[186],"analysis.":[189],"Trough":[190],"2-hr":[192],"1.7ng/ml":[197],"(range:1.1-7.1)":[198],"59.1ng/ml":[200],"(14.7-93.1),":[201],"respectively.":[202],"Higher":[203],"increases":[204],"from":[208],"baseline":[209],"significantly":[211,291],"associated":[212],"decline":[215,295],"(P=0.032)":[218],"(P=0.030).":[222],"14/18":[223],"had":[225],"PSA":[227],"response":[228],">50%,":[229],"radiologic":[230],"PR/CR":[231],"seen":[233],"10/14":[235],"lymph":[238],"node":[239],"mets":[240],"SD":[242],"9/10":[244],"mets.":[248],"Furthermore,":[249],"among":[250],"all":[251],"MDACC,":[255],"\u226535%":[257],"decrease":[258],"marker":[263,349],"uNTX":[264],"observed":[266],"\u223c50%":[268],"evaluable":[270],"pts.":[271],"Conclusions:":[272],"combination":[274],"+":[277],"is":[279],"effective":[280],"magnitude":[284],"increase":[287],"correlates":[292],"cytokines":[298],"MCP-1,":[301],"possibly":[302],"providing":[303],"mechanism":[305],"action":[307],"plus":[310],"t1/2":[314],"altered":[319],"this":[321],"setting.":[322],"These":[323],"findings":[324],"will":[325],"validated":[327],"ongoing":[330],"3":[332],"trial":[333],"prove":[344],"predictive":[348],"activity.":[352],"Author":[353],"Disclosure":[354],"Employment":[355],"or":[356,360],"Leadership":[357],"Position":[358],"Consultant":[359],"Advisory":[361],"Role":[362],"Stock":[363],"Ownership":[364],"Honoraria":[365],"Research":[366],"Funding":[367],"Expert":[368],"Testimony":[369],"Other":[370],"Remuneration":[371],"Bristol-Myers":[372,374],"Squibb":[373,375]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}